Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.74 |
| ▸ | MMP9 | P14780 | 3/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.74 |
| ▸ | MMP8 | P22894 | 2/20 | 0.74 |
| ▸ | GSK3B | P49841 | 3/20 | 0.72 |
| ▸ | BACE1 | P56817 | 3/20 | 0.72 |
| ▸ | MMP13 | P45452 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.65 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11928819 | 1.00 | MMP2 (0.74) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL13446382 | 1.00 | MMP2 (0.74) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL13358175 | 0.94 | GSK3B (0.71) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL16884580 | 0.94 | GSK3B (0.71) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL12291341 | 0.92 | GSK3B (0.65) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL13324431 | 0.91 | NFKB1 (0.83) | MMP2MMP9NFKB1MMP8GSK3B | |
| SCHEMBL6727006 | 0.90 | GSK3B (0.87) | MMP9NFKB1GSK3BBACE1MMP13 | |
| SCHEMBL3433171 | 0.90 | GSK3B (0.87) | MMP9NFKB1GSK3BBACE1MMP13 | |
| SCHEMBL242412 | 0.90 | GSK3B (0.87) | MMP9NFKB1GSK3BBACE1MMP13 | |
| SCHEMBL3680675 | 0.90 | GSK3B (0.87) | MMP9NFKB1GSK3BBACE1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11839637-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11672770-B2 | Oral ingestion composition | THERAVALUES CORPORATION (JP) | 2023-06-13 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-22 | — | — | US | disclosed |
| US-9907786-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-06 | — | — | US | disclosed |
| US-20170367997-A1 | THERAPEUTIC AGENT FOR CANCER | THERABIOPHARMA INC. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170239194-A1 | COMPOSITION FOR ORAL INTAKE | THERAVALUES CORPORATION (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9738623-B2 | Curcumin analogs | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20140248382-A1 | CURCUMINOID-BASED COMPOUND/STEVIOSIDE-CONTAINING COMPLEX FOR THE PREVENTION AND TREATMENT OF AN INFLUENZA VIRUS INFECTION | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-09-04 | — | — | US | disclosed |
| US-8545903-B2 | Composition for the prevention and treatment of influenza virus infection and composition for suppressing neuraminidase activity comprising turmeric extract | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-10-01 | — | — | US | disclosed |
| US-20130237609-A1 | CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS | EDGAR KEVIN J (US) | 2013-09-12 | — | — | US | disclosed |
| US-8470889-B2 | Hybrid-ionone and curcumin molecules as anticancer agents | TRT PHARMA INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20120219600-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20120107429-A1 | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract | BIOTEN CO., LTD. (KR) | 2012-05-03 | — | — | US | disclosed |
| US-20110294900-A1 | SELF EMULSIFYING DRUG DELIVERY SYSTEM FOR A CURCUMINOID BASED COMPOSITION | JAMIA HAMDARD (HAMDARD UNIVERSITY) (IN) | 2011-12-01 | — | — | US | disclosed |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC. (CA) | 2011-09-22 | — | — | US | disclosed |
| US-7682636-B2 | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 | METAPROTEOMICS, LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070141183-A1 | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 | METAPROTEOMICS, LLC (CA) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237609-A1 | CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS | KEAP1, NQO1, ABCG2 | MMP2 1679/4885MMP9 3243/4885NFKB1 81/4885 |
| US-11672770-B2 | Oral ingestion composition | FABP2, SI, FABP6 | MMP2 681/4885MMP9 1368/4885NFKB1 137/4885 |
| US-20120219600-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | MMP2 1001/4885MMP9 1732/4885NFKB1 3141/4885 |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | IKBKG, HSD17B11, IKBKE | MMP2 2560/4885MMP9 3918/4885NFKB1 55/4885 |
| US-20230190856-A1 | COMPOSITION COMPRISING A COMPLEX COMPRISING A CURCUMINOID COMPOUND, AND STEVIOL GLYCOSIDES OR A LICORICE EXTRACT OR A FRACTION THEREOF, AND USES THEREOF | CD4, IFNG, CD14 | MMP2 3015/4885MMP9 3405/4885NFKB1 447/4885 |
| US-20170239194-A1 | COMPOSITION FOR ORAL INTAKE | FABP2, SI, FABP6 | MMP2 575/4885MMP9 2324/4885NFKB1 428/4885 |
| US-20140248382-A1 | CURCUMINOID-BASED COMPOUND/STEVIOSIDE-CONTAINING COMPLEX FOR THE PREVENTION AND TREATMENT OF AN INFLUENZA VIRUS INFECTION | VIP, CRY1, MAVS | MMP2 2256/4885MMP9 3357/4885NFKB1 657/4885 |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | MMP2 1432/4885MMP9 2837/4885NFKB1 1602/4885 |
| US-20120107429-A1 | Composition For The Prevention And Treatment Of Influenza Virus Infection And Composition For Suppressing Neuraminidase Activity Comprising Turmeric Extract | NEU1, NEU3, NEU4 | MMP2 77/4885MMP9 114/4885NFKB1 359/4885 |
| US-20170367997-A1 | THERAPEUTIC AGENT FOR CANCER | CD274, PDCD1, PDCD1LG2 | MMP2 2656/4885MMP9 2796/4885NFKB1 258/4885 |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CRYAA, CRYAB, TTR | MMP2 1302/4885MMP9 3961/4885NFKB1 1082/4885 |
| US-20110294900-A1 | SELF EMULSIFYING DRUG DELIVERY SYSTEM FOR A CURCUMINOID BASED COMPOSITION | NPC1L1, SQLE, CYP46A1 | MMP2 2417/4885MMP9 3773/4885NFKB1 41/4885 |
| US-11839637-B2 | Neuron activator | BDNF, DBH, CHAT | MMP2 2522/4885MMP9 2867/4885NFKB1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.